Home » Newsletters » BioWorld Science

BioWorld Science

April 24, 2001

View Archived Issues

Data support vagus nerve stimulation for three different indications

Millennium reports company progress

Inex highlights past-year progress, updates 2001 milestones

72-week results from phase II study of Ceplene in hepatitis C patients

Proteome Sciences enters alliances to address neurodegenerative diseases

Achillion to explore new class of HIV drugs through NCI and NIAID collaboration

Intronn signs CRADA agreement for HPV treatment research

TV-3326, a new cholinesterase inhibitor with both neuroprotective and antidepressant effects

Reversible and nonselective MAO inhibitors in development for neurological diseases

Senetek's Invicorp safe and effective for severe ED in diabetics

AF-102B reduces CSF Abeta levels in Alzheimer's disease patients

Phase III data show Pharmacia's parecoxib reduces morphine use following surgery

Newron's lead compound has preclinical and early clinical profile suggestive of efficacy in PD

bioMerieux to acquire Organon Teknika's diagnostics business

Epigenesis and Hybridon join forces to develop antisense drugs for respiratory diseases

Chinese herbal preparation tested in patients with chronic HCV

Connetics finalizes Soltec acquisition

Potent anticoagulant activity of ART-123 associated with reduced effects on hemostasis

Interferon Sciences acquires significant stake in Metacine

NB-506 maintains activity against camptothecin-resistant human leukemia cells

Gene identified at Otsuka with potential in treatment or diagnosis of diabetes

Tricyclic PARP inhibitors and use in cancer therapy and for neurotoxicity Rx

Novel Lilly compounds particularly useful for NIDDM

Guilford presents new cyclophilin-binding neuroprotectants

Ramipril or ramiprilat may be useful for preventing stroke, diabetes and/or CHF

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...